NVAX stock price starting to rise as the realization that mRNA vaccines are worthless and toxic - even as the CDC and the USG tells you to keep getting them.

... is what drives the share price. NVAX offers solutions to bad...'s no 'bad news' the stock suffers or treads water. . So... the shine has faded from mRNA and the world continues to... as a better option than mRNA or Adeno. Free PR. . To... is indeed, a "Bad News Stock".

... is what drives the share price. NVAX offers solutions to bad...'s no 'bad news' the stock suffers or treads water. . So... the shine has faded from mRNA and the world continues to... as a better option than mRNA or Adeno. Free PR. . To... is indeed, a "Bad News Stock".

... stock is a screaming buy. There are only few biotechs that have mRNA... technology. The mRNA technology has the potential for... is an easy takeover target. MRNA - Stock price - 130 dollars Market cap ... 52 billion dollars BNTX - Stock price - 154 dollars Market cap ... 37 billion dollars ARCT - Stock price - 17 dollars Market cap ...

... stock is a screaming buy. There are only few biotechs that have mRNA... technology. The mRNA technology has the potential for... is an easy takeover target. MRNA - Stock price - 130 dollars Market cap ... 52 billion dollars BNTX - Stock price - 154 dollars Market cap ... 37 billion dollars ARCT - Stock price - 17 dollars Market cap ...

... the current stock price valuation here is unfair and Biontech's stock price is fair... BNT 161. It's a mRNA vaccine, being developed by Pfizer ...

... the current stock price valuation here is unfair and Biontech's stock price is fair... BNT 161. It's a mRNA vaccine, being developed by Pfizer ...

... some sort of review of MRNA and/or PFE's latest... advances in their mRNA vaccines? (Here's the link... business as normal keeping the mRNA vaccines on the front burner. ... the 'youngest kids' review for MRNA and PFE, assuming that these ... like they did with the mRNA vaccines or will they wait ... have no idea what the stock price will do... but if I ...

... some sort of review of MRNA and/or PFE's latest... advances in their mRNA vaccines? (Here's the link... business as normal keeping the mRNA vaccines on the front burner. ... the 'youngest kids' review for MRNA and PFE, assuming that these ... like they did with the mRNA vaccines or will they wait ... have no idea what the stock price will do... but if I ...

Originally Posted by DrJ "It's for Pfizer's stinky stock price!" Oh-yes-oh-yes-damn! Doesn't help MRNA stock price! They should recommend alternating the boosters between MRNA and Pfizer to benefit both stocks.

Originally Posted by DrJ "It's for Pfizer's stinky stock price!" Oh-yes-oh-yes-damn! Doesn't help MRNA stock price! They should recommend alternating the boosters between MRNA and Pfizer to benefit both stocks.

Hopefully when MRNA and BNTX vaccine go head ... and under shots, MRNA blows away BNTX and stock price reflect it. MRNA is so much...

Hopefully when MRNA and BNTX vaccine go head ... and under shots, MRNA blows away BNTX and stock price reflect it. MRNA is so much...

Moderna (MRNA) appears to be in oversold territory after a prolonged share-price drawdown. MRNA stock could be due for a rebound in light of encouraging news for Moderna. Investors should consider holding a MRNA shares

Moderna (MRNA) appears to be in oversold territory after a prolonged share-price drawdown. MRNA stock could be due for a rebound in light of encouraging news for Moderna. Investors should consider holding a MRNA shares

NVAX stock is manupulated at an extreme ... 1st generation mRNA vaccines bringing in more competition. However, Moderna stock is... expectations, stong forward looking guidance. Stock price will recover later this year...

NVAX stock is manupulated at an extreme ... 1st generation mRNA vaccines bringing in more competition. However, Moderna stock is... expectations, stong forward looking guidance. Stock price will recover later this year...

With all negative news on MRNA, PFE/BNTX vaccines and relevant valuations after recent stock price correction, NVAX should to be priced at $200 based on its current revenue guidance for similar multiple as Moderna.

With all negative news on MRNA, PFE/BNTX vaccines and relevant valuations after recent stock price correction, NVAX should to be priced at $200 based on its current revenue guidance for similar multiple as Moderna.